MAPT and Alzheimer disease: Double-labeling immunofluorescence analyses of VDAC1 and P-tau were conducted to ascertain whether P-tau also interacts with VDAC1 in the brains of AD patients and control subjects and in the brain tissues of transgenic and wild-type mice [42].